Characteristics of our hypoxemic COVID-19 pneumonia patients receiving corticosteroids and mortality-associated factors

References

• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020 May 1;130(5):2620–2629.
   PubMed Web of Science ®Google Scholar
• Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020 May 1;368(6490):473–474. Epub 2020 Apr 17. PMID: 32303591.
   PubMed Web of Science ®Google Scholar
• Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):1525–1531.
   Web of Science ®Google Scholar
• Arabi YM, Mandourah Y, Al-Hameed F, et al.; Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018 Mar 15;197(6):757–767. PMID: 29161116.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 —preliminary report. N Engl J Med. 2020;NEJMoa2021436. DOI:10.1056/NEJMoa2021436
   Web of Science ®Google Scholar
• Sterne JAC, Murthy S, et al.; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1–12.
   Web of Science ®Google Scholar
• COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. [ cited 2021 Jan 5]. Available from: https://www.covid19treatmentguidelines.nih.gov/
   Google Scholar
• Adult Patient Treatment of the Ministry of Health-The Study of the Scientific Advisory Board. 2020 Nov 7. Available from: https://covid19.saglik.gov.tr/Eklenti/40719/0/covid-19rehberieriskinhastayonetimivetedavipdf
   Google Scholar
• Papamanoli A, Yoo J, Grewal P, et al. High‐dose methylprednisolone in nonintubated patients with severe COVID‐19 pneumonia. Eur J Clin Invest. 2020 Dec 1;51:e13458.
   PubMed Web of Science ®Google Scholar
• Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2021 May 4;72(9):e373–e381.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Pijoan J, Bereciartua E, et al. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: an observational comparative study using routine care data. PLoS One. 2020;15(9):e0239401.
   PubMed Web of Science ®Google Scholar
• Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377–382.
   PubMed Web of Science ®Google Scholar
• The Study of the Scientific Advisory Board of the Ministry of Health on Anti-Inflammatory-Antisytokin Therapies, Management of Coagulopathy. 2020 Nov 7. Available from: https://covid19.saglik.gov.tr/TR-66341/antisitokin-antiinflamatuar-tedaviler-koagulopati-yonetimi.html
   Google Scholar
• Villar J, Ferrando C, Martínez D, et al.; Dexamethasone in ARDS Network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020 Mar;8(3):267–276. Epub 2020 Feb 7. PMID: 32043986
   PubMed Web of Science ®Google Scholar
• Russell L, Uhre KR, Lindgaard ALS; The COVID STEROID 2 Trial Group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia. The COVID STEROID 2 randomized trial. JAMA. Published online 2021 Oct 21;326:1807.
   PubMed Web of Science ®Google Scholar
• Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020 Dec 24;56(6):2002808.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–422.
   PubMed Web of Science ®Google Scholar
• Fadel R, Morrison A, Vahia A, et al. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis. 2020 Oct 15;71(16):2114–2120.
   PubMed Web of Science ®Google Scholar
• Fatima SA, Asif M, Khan KA, et al. Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe COVID-19 disease. Ann Med Surg. 2020 Dec;60:413–416.
   PubMed Web of Science ®Google Scholar
• Bradley P, Frost F, Tharmaratnam K, et al; NW Collaborative Organisation for Respiratory Research. Utility of established prognostic scores in COVID-19 hospital admissions: multicentre prospective evaluation of CURB-65, NEWS2 and qSOFA. BMJ Open Respir Res. 2020 Dec;7(1):e000729. PMID: 33293361; PMCID: PMC7722817.
   PubMed Web of Science ®Google Scholar
• Guo J, Zhou B, Zhu M, et al. CURB-65 may serve as a useful prognostic marker in COVID-19 patients within Wuhan, China: a retrospective cohort study. Epidemiol Infect. 2020 Oct 1;148:e241. PMID: 32998791; PMCID: PMC7573457
   PubMed Web of Science ®Google Scholar
• Armiñanzas C, Arnaiz de Las Revillas F, Gutiérrez Cuadra M, et al. Usefulness of the COVID-GRAM and CURB-65 scores for predicting severity in patients with COVID-19. Int J Infect Dis. 2021 Jul;108:282–288. Epub 2021 May 24. PMID: 34044145; PMCID: PMC8142713
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. PMID: 32171076; PMCID: PMC7270627.
   PubMed Web of Science ®Google Scholar
• COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47(1):60–73.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061–1069. Erratum in: JAMA. 2021 Mar 16;325(11):1113. PMID: 32031570; PMCID: PMC7042881.
   PubMed Web of Science ®Google Scholar
• Bertsimas D, Lukin G, Mingardi L, et al.; Hellenic COVID-19 Study Group. COVID-19 mortality risk assessment: an international multi-center study. PLoS One. 2020 Dec 9;15(12):e0243262.
   PubMed Web of Science ®Google Scholar
• Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One. 2020 Nov 17;15(11):e0241955.
   PubMed Web of Science ®Google Scholar
• Horby P, Mafham M, Linsell L, et al; RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020 Nov;383(21):2030–2040.
   PubMed Web of Science ®Google Scholar
• Elavarasi A, Prasad M, Seth T, et al. Chloroquine and hydroxychloroquine for the treatment of COVID-19: a systematic review and meta-analysis. J Gen Intern Med. 2020 Nov;35(11):3308–3314.
   PubMed Web of Science ®Google Scholar
• Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids — new mechanisms for old drugs. N Engl J Med. 2009 Oct;353(16):1711–1723.
   Google Scholar
• Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020 May;46(5):854–887. Epub 2020 Mar 28. PMID: 32222812; PMCID: PMC7101866.
   PubMed Web of Science ®Google Scholar
• Dequin PF, Heming N, Meziani F, et al.; CAPE COVID Trial Group and the CRICS-TriGGERSep Network. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020 Oct;324(13):1298–1306. PMID: 32876689; PMCID: PMC7489432
   PubMed Web of Science ®Google Scholar
• Li Q, Li W, Jin Y, et al. Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: a retrospective cohort study. Infect Dis Ther. 2020 Dec;9(4):823–836. Epub 2020 Sep 2. PMID: 32880102; PMCID: PMC7467137
   PubMed Web of Science ®Google Scholar
• Mammen MJ, Aryal K, Alhazzani W, et al. Corticosteroids for patients with acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials. Pol Arch Intern Med. 2020 Apr 30;130(4):276–286. Epub 2020 Mar 18. PMID: 32186831
   PubMedGoogle Scholar